In a subsequent clinical study, BRAFi ± MEKi increased intratumoral CD8+ T cell density, cytotoxicity‐associated proteins, and melanoma differentiation antigen expression, as well as decreased immunosuppressive cytokines within the first 2 weeks of treatment [5]. Here, CD8A is linked to melanoma.